Three different studies described significant associations with patients’ survival by assessing MTHFD2 immunolabeling in 78 esophageal carcinoma samples, 323 lung cancer samples, and 137 RCC cases [19, 39, 47, 48]. This evidence concerns the gene MTHFD2 and lung carcinoma.